Cargando…
Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023
During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April–June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416574/ https://www.ncbi.nlm.nih.gov/pubmed/37561053 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.32.2300397 |
| _version_ | 1785087811454500864 |
|---|---|
| author | Fabiani, Massimo Mateo-Urdiales, Alberto Sacco, Chiara Rota, Maria Cristina Fotakis, Emmanouil Alexandros Petrone, Daniele Del Manso, Martina Siddu, Andrea Stefanelli, Paola Bella, Antonino Riccardo, Flavia Rezza, Giovanni Palamara, Anna Teresa Brusaferro, Silvio Pezzotti, Patrizio |
| author_facet | Fabiani, Massimo Mateo-Urdiales, Alberto Sacco, Chiara Rota, Maria Cristina Fotakis, Emmanouil Alexandros Petrone, Daniele Del Manso, Martina Siddu, Andrea Stefanelli, Paola Bella, Antonino Riccardo, Flavia Rezza, Giovanni Palamara, Anna Teresa Brusaferro, Silvio Pezzotti, Patrizio |
| author_sort | Fabiani, Massimo |
| collection | PubMed |
| description | During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April–June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available. |
| format | Online Article Text |
| id | pubmed-10416574 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | European Centre for Disease Prevention and Control (ECDC) |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104165742023-08-12 Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023 Fabiani, Massimo Mateo-Urdiales, Alberto Sacco, Chiara Rota, Maria Cristina Fotakis, Emmanouil Alexandros Petrone, Daniele Del Manso, Martina Siddu, Andrea Stefanelli, Paola Bella, Antonino Riccardo, Flavia Rezza, Giovanni Palamara, Anna Teresa Brusaferro, Silvio Pezzotti, Patrizio Euro Surveill Rapid Communication During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April–June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available. European Centre for Disease Prevention and Control (ECDC) 2023-08-10 /pmc/articles/PMC10416574/ /pubmed/37561053 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.32.2300397 Text en This article is copyright of the authors or their affiliated institutions, 2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
| spellingShingle | Rapid Communication Fabiani, Massimo Mateo-Urdiales, Alberto Sacco, Chiara Rota, Maria Cristina Fotakis, Emmanouil Alexandros Petrone, Daniele Del Manso, Martina Siddu, Andrea Stefanelli, Paola Bella, Antonino Riccardo, Flavia Rezza, Giovanni Palamara, Anna Teresa Brusaferro, Silvio Pezzotti, Patrizio Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023 |
| title | Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023 |
| title_full | Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023 |
| title_fullStr | Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023 |
| title_full_unstemmed | Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023 |
| title_short | Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023 |
| title_sort | relative effectiveness of bivalent original/omicron ba.4-5 mrna vaccine in preventing severe covid-19 in persons 60 years and above during sars-cov-2 omicron xbb.1.5 and other xbb sublineages circulation, italy, april to june 2023 |
| topic | Rapid Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416574/ https://www.ncbi.nlm.nih.gov/pubmed/37561053 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.32.2300397 |
| work_keys_str_mv | AT fabianimassimo relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT mateourdialesalberto relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT saccochiara relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT rotamariacristina relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT fotakisemmanouilalexandros relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT petronedaniele relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT delmansomartina relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT sidduandrea relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT stefanellipaola relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT bellaantonino relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT riccardoflavia relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT rezzagiovanni relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT palamaraannateresa relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT brusaferrosilvio relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT pezzottipatrizio relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 AT relativeeffectivenessofbivalentoriginalomicronba45mrnavaccineinpreventingseverecovid19inpersons60yearsandaboveduringsarscov2omicronxbb15andotherxbbsublineagescirculationitalyapriltojune2023 |